Precigen, Inc.

NASDAQ:PGEN

Biotechnology

Healthcare
$4.27 -2.08%

-$0.10 today

Market cap
$1.53B
Beta
1.06
P/E (TTM)
-7.1
EPS (TTM)
-$0.65
52W Low $1.39High $5.47

Volume 4.27M

Average 4.72M

PGEN Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Precigen, Inc.NASDAQ: PGEN

Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026

Accumulated OCI turns negative

Q2 FY2026 Accumulated OCI was -$29K, compared with $11K a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -363.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$29K-70.6% QoQ
Last fiscal yearDec 2025
$7K-41.7% YoY
Year agoJun 2025
$11K-363.6% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-363.6%——
1 year-41.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
7K USD
Year-over-year change
-41.7%
4-year CAGR
-56.9%

Accumulated OCI vs competitors

How PGEN compares with its peers on the latest reported figures

  • PGEN's Jun 2026 Accumulated OCI of -$29K is the 4th highest of the 8 companies compared; the peer median is -$112K.
  • Its year-over-year change of -363.6% is the 6th highest of 7, against a peer median of -111.4%.
  • Accumulated OCI amounts to 0.0% of total assets for PGEN, versus a peer median of 0.0%.
PGEN Competitors Peer median
Accumulated OCI for PGEN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EDITEditas Medicine, Inc.Mar 2026$0 -100.0%—0.0%
DTILPrecision BioSciences, Inc.Mar 2026$0 ——0.0%
ABEOAbeona Therapeutics Inc.Mar 2026-$21K +68.7%—0.0%
PGENPrecigen, Inc.Jun 2026-$29K -363.6%—0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026-$112K -314.8%—0.0%
NTLAIntellia Therapeutics, Inc.Mar 2026-$240K -122.7%—0.0%
RGNXREGENXBIO Inc.Mar 2026-$870K -14.2%—0.3%
CRSPCRISPR Therapeutics AGSep 2026-$14.08M -382.5%—0.6%
Peer median (excluding PGEN) -$112K-111.4%—0.0%

Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.42M4.86M7.58M29.52M30.23M
Short-term Investments72.24M51.09M55.28M68.39M67.62M
Net Receivables1.98M13.8M1.58M1.16M4.36M
Inventory326K287K009.58M
Other Current Assets38.92M48.12M4.33M3.34M3.43M
Total Current Assets156.63M118.16M68.76M102.41M115.24M
Property, Plant & Equipment (Net)18.55M15.29M14.13M18.8M18.44M
Goodwill37.55M36.92M26.61M19.14M15.23M
Intangible Assets52.29M44.46M40.7M4.46M3.18M
Long-term Investments48.56M399K002.51M
Tax Assets09.17M001.12M
Other Non-current Assets46.27M(8.42M)846K459K908K
Total Non-current Assets203.23M97.82M82.29M42.85M41.39M
Total Assets359.86M215.98M151.04M145.27M156.62M
Account Payables3.11M4.07M1.73M3.53M11.99M
Short-term Debt52K43.22M000
Tax Payables00000
Deferred Revenue1.49M25K509K589K517K
Other Current Liabilities20.71M23.75M8.25M8.42M10.2M
Total Current Liabilities34.65M78.65M22.99M21.52M37.31M
Long-term Debt179.88M00093.17M
Deferred Tax Liabilities2.54M2.26M1.85M01.12M
Deferred Revenue (Non-current)23.02M1.82M1.82M1.93M0
Other Non-current Liabilities3.67M0078.76M134K
Total Non-current Liabilities217.86M11.07M9.56M85.24M98.4M
Total Liabilities252.51M89.72M32.55M106.75M135.71M
Common Stock00000
Retained Earnings(1.92B)(1.87B)(1.96B)(2.09B)(2.34B)
Accumulated OCI203K(3.49M)(1.95M)12K7K
Other Stockholders Equity00000
Minority Interest00000
Total Equity107.35M126.26M118.5M38.51M20.91M
Total Debt190.07M51.42M7.1M5.5M98.29M
Net Debt153.65M46.56M(481K)(24.02M)68.06M

Precigen, Inc.

NASDAQ:PGEN

Intrinsic Alpha fair value

Locked

Current Price

$4.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.